(Q37053886)

17 August 2017

1 reference

title

Pharmacology and new perspectives of angiotensin II receptor blocker in prostate cancer treatment (English)

1 reference

17 August 2017

1 reference

1 reference

Hiroji Uemura

1

1 reference

17 August 2017

Hitoshi Ishiguro

series ordinal

2

1 reference

17 August 2017

Yoshinobu Kubota

series ordinal

3

1 reference

17 August 2017

publication date

1 January 2008

1 reference

International Journal of Urology

17 August 2017

published in

1 reference

17 August 2017

volume

15

1 reference

17 August 2017

issue

1

1 reference

17 August 2017

page(s)

19-26

1 reference

17 August 2017

cites work

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

Studies on Prostatic Cancer: I. The Effect of Castration, Of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

The renin angiotensin system in the regulation of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

Association between captopril, other antihypertensive drugs and risk of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

Androgen deprivation therapy for prostate cancer: current status and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

Androgen Receptor (AR) Coregulators: An Overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

Expression of AR associated protein 55 (ARA55) and androgen receptor in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

IL-1 is required for tumor invasiveness and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

Interaction of IGF signaling and the androgen receptor in prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

Expression of interleukin-8 correlates with angiogenesis, tumorigenicity, and metastasis of human prostate cancer cells implanted orthotopically in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

Spectrum of use for the angiotensin-receptor blocking drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

Regulation of cell proliferation and growth by angiotensin II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

The renin-angiotensin system and vascular hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

Tissue renin-angiotensin systems: new insights from experimental animal models in hypertension research

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

Physiology and pathophysiology of the adipose tissue renin-angiotensin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

Physiological genomic analysis of the brain renin-angiotensin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

Renin-angiotensin system is an important factor in hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

Current topic: the uteroplacental renin-angiotensin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

Substrate specificity of tonin from rat submaxillary gland

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

High levels of human chymase expression in the pineal and pituitary glands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

Transcription of the prorenin gene in normal and diseased breast.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

AT1 angiotensin II receptor subtype in the human larynx and squamous laryngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

Enhancement of aminopeptidase A expression during angiotensin II-induced choriocarcinoma cell proliferation through AT1 receptor involving protein kinase C- and mitogen-activated protein kinase-dependent signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

Molecular cloning and expression of the gene encoding human angiotensin II type 2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

Angiotensin II's antiproliferative effects mediated through AT2-receptors depend on down-regulation of SM-20

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

Angiotensin II type 1 receptor blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

Angiotensin II receptor pharmacology and AT1-receptor blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

Angiotensin receptors: a new role in cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

Dysregulated expression of growth factors and their receptors in the development of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

Inflammation and angiotensin II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

Antiproliferative activity of angiotensin II receptor blocker through cross-talk between stromal and epithelial prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

ERK and p38 MAPK, but not NF-kappaB, are critically involved in reactive oxygen species-mediated induction of IL-6 by angiotensin II in cardiac fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

Angiotensin II-induced genomic damage in renal cells can be prevented by angiotensin II type 1 receptor blockage or radical scavenging

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

Angiotensin II blocker decreases serum prostate specific antigen in hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

The angiotensin II AT2 receptor inhibits proliferation and promotes differentiation in PC12W cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

AT1 receptor is present in glioma cells; its blockage reduces the growth of rat glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

PPARgamma : a nuclear regulator of metabolism, differentiation, and cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

The PPARs: from orphan receptors to drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

The mechanisms of action of PPARs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

PPAR(gamma) and glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

Regulation of prostate cancer cell growth and PSA expression by angiotensin II receptor blocker with peroxisome proliferator-activated receptor gamma ligand like action

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

Peroxisome proliferator-activated receptor- gamma expression in human malignant and normal brain, breast and prostate-derived cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

Endothelium-derived factors as paracrine mediators of prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01937.X

10.1111/J.1442-2042.2007.01937.X

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference